CVE-2019-1010307

Public Exploit

Description

GLPI GLPI Product 9.3.1 is affected by: Cross Site Scripting (XSS). The impact is: All dropdown values are vulnerable to XSS leading to privilege escalation and executing js on admin. The component is: /glpi/ajax/getDropDownValue.php. The attack vector is: 1- User Create a ticket , 2- Admin opens another ticket and click on the "Link Tickets" feature, 3- a request to the endpoint fetches js and executes it.

Category

5.4
CVSS
Severity: Medium
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.25%
Third-Party Advisory github.com Third-Party Advisory github.com
Affected: GLPI GLPI Product
Published at:
Updated at:

References

Link Tags
https://github.com/glpi-project/glpi/releases/tag/9.3.1 third party advisory release notes
https://github.com/glpi-project/glpi/blob/9.4/bugfixes/ajax/getDropdownValue.php third party advisory exploit

Frequently Asked Questions

What is the severity of CVE-2019-1010307?
CVE-2019-1010307 has been scored as a medium severity vulnerability.
How to fix CVE-2019-1010307?
To fix CVE-2019-1010307, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2019-1010307 being actively exploited in the wild?
It is possible that CVE-2019-1010307 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2019-1010307?
CVE-2019-1010307 affects GLPI GLPI Product.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.